Trials / Conditions / Muscular Disorders, Atrophic

Muscular Disorders, Atrophic

14 registered clinical trials studyying Muscular Disorders, Atrophic — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT) NCT07521930	Johns Hopkins University	N/A
Recruiting	Dietary Strategy to Tackle Cognitive and Locomotor Abilities in Early Elderly Subjects NCT06871384	University Rovira i Virgili	N/A
Completed	Molecular Mechanisms Underlying Anabolic Resistance to Protein Intake During Muscle Disuse NCT06228742	United States Army Research Institute of Environmental Medicine	N/A
Completed	What Are the Effects of Lower Limb Dysmetria on Gluteus Medius and Erector Spinae Musculature? NCT06217835	Camilo Jose Cela University	N/A
Unknown	Bruxism and Underlying Psichological Factors NCT06289608	University of Salamanca	—
Completed	Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers NCT05730842	Edgewise Therapeutics, Inc.	Phase 1
Completed	Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients NCT05479981	Avidity Biosciences, Inc.	Phase 2
Active Not Recruiting	A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy NCT05126758	Capricor Inc.	Phase 3
Completed	A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy NCT03406780	Capricor Inc.	Phase 2
Completed	Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy NCT03179631	PTC Therapeutics	Phase 3
Terminated	An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy NCT02090959	PTC Therapeutics	Phase 3
Completed	Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) NCT01826487	PTC Therapeutics	Phase 3
Unknown	Diagnostic Accuracy of MR in Myositis NCT01702870	University of Warwick	—
Available	Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping NCT07250737	Avidity Biosciences, Inc.	—